Richard W. Birkinshaw
Parkville, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Computational design of potent and selective binders of BAK and BAX.
Journal: Science advances
Published: September 05, 2025
MK-7602: a potent multi-stage dual-targeting antimalarial.
Journal: EBioMedicine
Published: June 23, 2025
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.
Journal: Science advances
Published: March 05, 2025
The E3-ome gene-centric compendium reveals the human E3 ligase landscape.
Journal: Cell
Published: February 16, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Journal: Leukemia
Published: February 04, 2025
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.
Journal: Nature communications
Published: December 18, 2024
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia.
Journal: Blood advances
Published: August 05, 2024
Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis.
Journal: PLoS biology
Published: December 23, 2023
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors.
Journal: Frontiers in chemistry
Published: January 24, 2022
VDAC2 and the BCL-2 family of proteins.
Journal: Biochemical Society transactions
Published: October 18, 2021
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
Journal: Structure (London, England : 1993)
Published: October 15, 2021
Last Updated: 09/26/2026